Efficacy of N-terminal pro-brain natriuretic peptide digit number for screening of cardiac disease in new haemodialysis patients

被引:8
作者
Iwasaki, Masaki [1 ]
Joki, Nobuhiko [1 ]
Tanaka, Yuri [1 ]
Ikeda, Nobutaka [2 ]
Hayashi, Toshihide [1 ]
Kubo, Shun [1 ]
Asakawa, Takasuke [1 ]
Takahashi, Yasunori [3 ]
Hirahata, Koichi [4 ]
Imamura, Yoshihiko [3 ]
Hase, Hiroki [1 ]
机构
[1] Toho Univ, Ohashi Med Ctr, Div Nephrol, Tokyo 1538515, Japan
[2] Toho Univ, Ohashi Med Ctr, Div Cardiol, Tokyo 1538515, Japan
[3] Nissan Tamagawa Hosp, Div Dialysis, Tokyo, Japan
[4] Hirahata Clin, Tokyo, Japan
关键词
cardiovascular disease; digit number; initiation of dialysis; NT-proBNP; screening; CORONARY-ARTERY-DISEASE; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; TROPONIN-T; MORTALITY; ATHEROSCLEROSIS; MALNUTRITION; INFLAMMATION; HYPERTROPHY; BIOMARKERS;
D O I
10.1111/nep.12063
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim The usefulness of the absolute N-terminal pro-brain natriuretic peptide (NT-ProBNP) concentration and its digit number for screening for cardiac disease was explored in new haemodialysis patients. Methods A cross-sectional study involving 71 (68 +/- 14 years, 83% male) new dialysis patients was conducted. Receiver operator characteristic curve analysis was performed to identify the cutoff level of NT-proBNP for identifying cardiac disease at the start of dialysis. Results The median NT-proBNP concentration was 6576pg/mL just before the first dialysis session and its mean digit number was 4.3 +/- 0.6. Overall, 67%, 52%, 9% and 35% of patients had left ventricular (LV) hypertrophy, LV dilatation, systolic dysfunction and significant coronary artery disease, respectively. NT-proBNP levels of about 6000, 10000 and 14000pg/mL were the best cutoff levels for the diagnosis of coronary artery disease (AUC, 0.754; P<0.001), LV systolic dysfunction (area under the curve (AUC), 0.765, P=0.001) and LV dilatation (AUC, 0.685, P=0.008), respectively. Interestingly, 4.5 was the best digit number cutoff for all cardiac abnormalities. These findings suggest that a digit number of 5 or more means a potentially high risk for cardiovascular disease and a digit number of 3 or less means a relatively low risk. Conclusions The NT-proBNP concentration just before the first dialysis session is a useful tool for screening for cardiac abnormalities. Considering the wide variation of the NT-proBNP cutoff levels depending on each cardiac abnormality, the digit number could be potentially easier to use for initial risk stratification for cardiac disease in new dialysis patients.
引用
收藏
页码:497 / 504
页数:8
相关论文
共 27 条
[1]   Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death [J].
Apple, FS ;
Murakami, MM ;
Pearce, LA ;
Herzog, CA .
CLINICAL CHEMISTRY, 2004, 50 (12) :2279-2285
[2]   K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients [J].
Bolton, K ;
Beddhu, S ;
Campese, VM ;
Chavers, BM ;
Cheung, AK ;
Churchill, DN ;
Goldstein-Fuchs, J ;
Herzog, CA ;
Henrich, W ;
King, K ;
Kronenberg, F ;
Miholics, BS ;
Painter, PL ;
Parekh, R ;
Roberts, MS ;
Stehman-Breen, C ;
Stenvinkel, P ;
Wali, R ;
Weiss, MF .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) :S7-S153
[3]   Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis [J].
David, Sascha ;
Kuempers, Philipp ;
Seidler, Vega ;
Biertz, Frank ;
Haller, Hermann ;
Fliser, Danilo .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (04) :1370-1377
[4]   Should we screen for coronary artery disease in asymptomatic chronic dialysis patients? [J].
De Vriese, An S. ;
Vandecasteele, Stefaan J. ;
Van den Bergh, Barbara ;
De Geeter, Frank W. .
KIDNEY INTERNATIONAL, 2012, 81 (02) :143-151
[5]   Atherosclerosis in CKD: differences from the general population [J].
Drueeke, Tilman B. ;
Massy, Ziad A. .
NATURE REVIEWS NEPHROLOGY, 2010, 6 (12) :723-735
[6]   European guidelines on cardiovascular disease prevention in clinical practice: executive summary [J].
Graham, Ian ;
Atar, Dan ;
Borch-Johnsen, Knut ;
Boysen, Gudrun ;
Burell, Gunilla ;
Cifkova, Renata ;
Dallongeville, Jean ;
De Backer, Guy ;
Ebrahim, Shah ;
Gjelsvik, Bjorn ;
Herrman-Lingen, Christoph ;
Hoes, Arno ;
Humphries, Steve ;
Knapton, Mike ;
Perk, Joep ;
Priori, Silvia G. ;
Pyorala, Kalevi ;
Reiner, Zeljko ;
Ruilope, Luis ;
Sans-Menendez, Susana ;
Reimer, Wilma Scholte op ;
Weissberg, Peter ;
Wood, David ;
Yarnell, John ;
Zamorano, Jose Luis .
EUROPEAN HEART JOURNAL, 2007, 28 (19) :2375-2414
[7]   Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio [J].
Jensen, Juliana ;
Ma, Li-Ping ;
Fu, Michael L. X. ;
Svaninger, David ;
Lundberg, Per-Arne ;
Hammarsten, Ola .
CLINICAL RESEARCH IN CARDIOLOGY, 2010, 99 (07) :445-452
[8]   Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease [J].
Joki, N ;
Hase, H ;
Nakamura, R ;
Yamaguchi, T .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (04) :718-723
[9]   N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients [J].
Khan, Ijaz A. ;
Fink, Jeffrey ;
Nass, Caitlin ;
Chen, Hegang ;
Christenson, Robert ;
deFilippi, Christopher R. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (10) :1530-1534
[10]   N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis [J].
Madsen, L. H. ;
Ladefoged, S. ;
Corell, P. ;
Schou, M. ;
Hildebrandt, P. R. ;
Atar, D. .
KIDNEY INTERNATIONAL, 2007, 71 (06) :548-554